Q2 2026 revenues rose 17% to $4.3B, led by record sales of Dupixent, EYLEA HD, and Libtayo. Non-GAAP EPS grew 11% to $14.29, and the Sanofi Development Balance was fully repaid, boosting future collaboration profits. Regulatory and pipeline progress continued.Original document: Regeneron Pharmaceut…
Q2 2026 revenues rose 17% to $4.3B, led by record sales of Dupixent, EYLEA HD, and Libtayo. Non-GAAP EPS grew 11% to $14.29, and the Sanofi Development Balance was fully repaid, boosting future collaboration profits. Regulatory and pipeline progress continued.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
